共 50 条
- [21] Safety and efficacy of continuous subcutaneous levodopa-carbidopa infusion (ND0612) for Parkinson's disease with motor fluctuations (BouNDless): a phase 3, randomised, double-blind, double-dummy, multicentre trial (vol 43, pg 465, 2024)LANCET NEUROLOGY, 2024, 23 (06): : E10 - E10Espay, A. J.Stocchi, F.Pahwa, R.
- [22] Efficacy and Safety of Mildronate for Acute Ischemic Stroke: A Randomized, Double-Blind, Active-Controlled Phase II Multicenter TrialClinical Drug Investigation, 2013, 33 : 755 - 760Yi ZhuGuangyun ZhangJun ZhaoDeshuai LiXiaodong YanJuanfang LiuXuedong LiuHaibo ZhaoJielai XiaXiao ZhangZhengyi LiBaorong ZhangZongcheng GuoLianyuan FengZhaodong ZhangFang QuGang Zhao
- [23] Efficacy and Safety of Mildronate for Acute Ischemic Stroke: A Randomized, Double-Blind, Active-Controlled Phase II Multicenter TrialCLINICAL DRUG INVESTIGATION, 2013, 33 (10) : 755 - 760Zhu, YiZhang, GuangyunZhao, JunLi, DeshuaiYan, XiaodongLiu, JuanfangLiu, XuedongZhao, HaiboXia, JielaiZhang, XiaoLi, ZhengyiZhang, BaorongGuo, ZongchengFeng, LianyuanZhang, ZhaodongQu, FangZhao, Gang
- [24] Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 StudyNeurology and Therapy, 2023, 12 (6) : 1937 - 1958Jason AldredEric Freire-AlvarezAlexander V. AmelinAngelo AntoniniBruno BergmansFilip BergquistManon BouchardKumar BudurCamille CarrollK. Ray ChaudhuriSusan R. CriswellErik H. DanielsenFlorin GandorJia JiaThomas E. KimberHideki MochizukiWeining Z. RobiesonAmy M. SpiegelDavid G. StandaertSaritha TalapalaMaurizio F. FacherisVictor S. C. Fung
- [25] Efficacy of opicapone in Parkinson's disease patients with motor fluctuations: A phase III, randomized, double-blind, placebo and active-controlled study - BIPARK IMOVEMENT DISORDERS, 2015, 30 : S85 - S86Ferreira, J.Lees, A.Santos, A.Pinto, R.Lopes, N.Nunes, T.Rocha, J. F.Soares-da-Silva, P.
- [26] Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial (vol 21, pg 923, 2020)LANCET ONCOLOGY, 2020, 21 (07): : E341 - E341Blay, J-YSerrano, C.Heinrich, M. C.
- [27] Safety and efficacy of continuous subcutaneous levodopa-carbidopa infusion (ND0612) for Parkinson's disease with motor fluctuations (BouNDless): a phase 3, randomised, double-blind, double-dummy, multicentre trialLANCET NEUROLOGY, 2024, 23 (05): : 465 - 476Espay, Alberto J.Stocchi, FabrizioPahwa, RajeshAlbanese, AlbertoEllenbogen, AaronFerreira, Joaquim J.Giladi, NirGurevich, TanyaHassin-Baer, SharonHernandez-Vara, JorgeIsaacson, Stuart H.Kieburtz, KarlLewitt, Peter A.Lopez-Manzanares, LydiaOlanow, C. WarrenPoewe, WernerSarva, HariniYardeni, TamiAdar, LiatSalin, LaurenceLopes, NelsonSasson, NissimCase, RyanRascol, Olivier
- [28] A Randomized, Double-blind, Active-controlled Exploratory Clinical Trial for the Evaluation of the Efficacy and Safety of Goodmorning S Granule® on ConstipationKOREAN JOURNAL OF GASTROENTEROLOGY, 2022, 80 (01): : 17 - 27Ju, MunjinKim, NayoungShin, Cheol MinPark, Young SooYoon, HyukChoi, YonghunLee, Dong Ho
- [29] Efficacy of biologically-directed daylight therapy on sleep and circadian rhythm in Parkinson's disease: a randomised, double-blind, parallel-group, active-controlled, phase 2 clinical trialECLINICALMEDICINE, 2024, 69Feigl, BeatrixLewis, Simon J. G.Burr, Lucy D.Schweitzer, DanielGnyawali, SubodhVagenas, DimitriosCarter, Drew D.Zele, Andrew J.
- [30] Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson's Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study (vol 12, 1937, 2023)NEUROLOGY AND THERAPY, 2023, 12 (06) : 1959 - 1960Aldred, JasonFreire-Alvarez, EricAmelin, Alexander V.Antonini, AngeloBergmans, BrunoBergquist, FilipBouchard, ManonBudur, KumarCarroll, CamilleChaudhuri, K. RayCriswell, Susan R.Danielsen, Erik H.Gandor, FlorinJia, JiaKimber, Thomas E.Mochizuki, HidekiRobieson, Weining Z.Spiegel, Amy M.Standaert, David G.Talapala, SarithaFacheris, Maurizio F.Fung, Victor S. C.